Evidence map›Paper›PMID 37101716›Full record

ArticleEvidence-based complementary and alternative medicine : eCAM2023

Pan-Cancer Analysis of Prognostic and Immune Infiltrates for the TMEM65, Especially for the Breast Cancer.

Xinming Song, Pintian Wang, Ruiling Feng, Mandika Chetry, E Li, Xiaohua Wu, Zewa Liu, Shasha Liao, Jing Lin

RetractedOpen access · hybridAbstract readRetracted Publication
In one paragraph

Article in Evidence-based complementary and alternative medicine : eCAM, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Xinming SongDepartment of Oncology, The First Affiliated Hospital of Shantou University Medical College, Shantou 515041, Guangdong, China.ORCID https://orcid.org/0000-0003-1711-6539
Pintian WangDepartment of Oncology, The First Affiliated Hospital of Shantou University Medical College, Shantou 515041, Guangdong, China.
Ruiling FengDepartment of Oncology, The First Affiliated Hospital of Shantou University Medical College, Shantou 515041, Guangdong, China.
Mandika ChetryDepartment of Oncology, The First Affiliated Hospital of Shantou University Medical College, Shantou 515041, Guangdong, China.
E LiDepartment of Oncology, Shantou Longhu People's Hospital, Shantou, Guangdong, China.
Xiaohua WuDepartment of Oncology, Shantou Longhu People's Hospital, Shantou, Guangdong, China.
Zewa LiuDepartment of Oncology, The First Affiliated Hospital of Shantou University Medical College, Shantou 515041, Guangdong, China.
Shasha LiaoDepartment of Oncology, Shantou Longhu People's Hospital, Shantou, Guangdong, China.
Jing LinDepartment of Oncology, The First Affiliated Hospital of Shantou University Medical College, Shantou 515041, Guangdong, China.ORCID https://orcid.org/0000-0001-5571-5925
Shantou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Transmembrane protein 65 (TMEM65) is an inner mitochondrial membrane protein, which played important role in mediating autophagy, smooth muscle contraction, protein glycosylation, and immune response. In recent years, the interest had risen for exploring the function of the TMEM genes in the cancer fields. As a consequence, in our pan-cancer research of the TMEM65, we explored the function of the gene in kinds of database and tried to apply the finding in the clinical practice. Methods: In this research, we provide a comprehensive investigation of TMEM65 expression in a pan-cancer manner containing 33 cancer types. We evaluated the association of TMEM65 with the prognosis, immune infiltration, drug sensitivity analysis, GSVA enrichment analysis, TMB, MSI, NEO, and hotspot mechanisms. Results: TMEM65 was abnormally expressed in 24 types of cancers and showed correlation with the OS for 6 cancers and PFI for 9 cancers and kpI for 3 types. Moreover, the TME score, CD8 T effector, and immune checkpoint scoring systems showed a close correlation with the TMEM65. Moreover, TMEM65 was strongly correlated with some of the most common tumor-related genes and certain pathways (TGF beta signaling, TNFA signaling, hypoxia, pyroptosis, DNA repairing, autophagy, ferroptosis, and other related genes). Additionally, the TMEM65 showed correlations with the tumor mutational burden (TMB), microsatellite instability (MSI), NEO, and drug sensitivity. Finally, we confirmed several pathways by the GSEA and GSVA for the TMEM65 at the breast cancer aspects. Nomogram prediction model was also established for the breast tumors based on the TMEM65 level and other variables. Conclusion: Above all, the TMEM65 played important roles in predicting the prognosis of the cancers and correlated with the tumor immunity in the pan-cancer analysis.

Identifiers

PMID37101716
PMCPMC10125759
OpenAlexW4366204963

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.